Skip to main content

Advertisement

SpringerLink
Log in

Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy

  • Immuno-oncology (RM Bukowski and JH Finke, Section Editors)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review provides a comprehensive assessment of recent literature reports describing atypical response patterns observed with immune checkpoint inhibitors (ICIs), modifications to response evaluation criteria for ICIs, and treatment beyond progression in clinical trials.

Recent Findings

Certain response patterns such as durable response, pseudoprogression, hyperprogression, and dissociated responses can be seen with ICI treatment. These patterns carry differing prognoses and are associated with varied factors. There are multiple modifications of standard Response Evaluation Criteria in Solid Tumors (RECIST) that have been proposed to better characterize immunotherapy response; however, standard RECIST1.1 remains most commonly used in clinical trials. Treatment beyond progression varies in frequency and benefit depending on assessment criteria and cancer type.

Summary

Future research incorporating modified imaging criteria and biomarker assessments may serve to clarify who will benefit most from treatment beyond progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–84. https://doi.org/10.1200/jco.2017.77.0412.

  2. Drugs@fda [database on the Internet]. U.S Food and Drug Administration. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed: March, 2020.

  3. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541–3. https://doi.org/10.1200/jco.2015.61.6870.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30(3):385–96. https://doi.org/10.1093/annonc/mdz003.

  5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

  6. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e52. https://doi.org/10.1016/s1470-2045(17)30074-8.

  7. U.S. National Institutes of Health ClinicalTrials. gov registry. https://clinicaltrials.gov/ct2/resultsterm=cancer+immuno+therapy&Search=Search. Accessed March 2020.

  8. McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013–20. https://doi.org/10.1200/jco.2014.58.1041.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hodi FS, Kluger H, Sznol M, Carvajal R, Lawrence D, Atkins M, et al. Abstract CT001: durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Cancer Res. 2016;76(14 Supplement):CT001-CT. https://doi.org/10.1158/1538-7445.Am2016-ct001.

    Article  Google Scholar 

  10. Long GV, Schachter J, Ribas A, Arance AM, Grob J-J, Mortier L, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. J Clin Oncol. 2018;36(15_suppl):9503. https://doi.org/10.1200/JCO.2018.36.15_suppl.9503.

    Article  Google Scholar 

  11. • Pons-Tostivint E, Latouche A, Vaflard P, Ricci F, Loirat D, Hescot S, et al. Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials. JCO Precis Oncol. 2019;3:1–10. https://doi.org/10.1200/po.18.00114. Analysis based on extracted data from phase-III trials of ICI agents that were approved between 2000 and 2018. This article notes the inconsistency in the definition of durable responses across studies and presented results for durable responses, defined based on PFS and OS, with ICI-agents compared to durable responses with non-ICI agents.

  12. McCoach CE, Blumenthal GM, Zhang L, Myers A, Tang S, Sridhara R, et al. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol. 2017;28(11):2707–14. https://doi.org/10.1093/annonc/mdx414.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Osgood C, Mulkey F, Mishra-Kalyani PS, Lemery S, Ward A, Keegan P, et al. FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (UMM) by therapy type. J Clin Oncol. 2019;37(15_suppl):9508. https://doi.org/10.1200/JCO.2019.37.15_suppl.9508.

    Article  Google Scholar 

  14. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86. https://doi.org/10.1158/2159-8290.Cd-18-0367.

    Article  PubMed  Google Scholar 

  15. Long GV, Weber JS, Larkin J, Atkinson V, Grob J-J, Schadendorf D, et al. Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. JAMA Oncol. 2017;3(11):1511–9. https://doi.org/10.1001/jamaoncol.2017.1588.

  16. Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58(8):1297–306. https://doi.org/10.1007/s00262-008-0642-y.

    Article  CAS  PubMed  Google Scholar 

  17. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21(8):1712–7. https://doi.org/10.1093/annonc/mdq013.

  18. Borcoman E, Nandikolla A, Long G, Goel S, Tourneau CL. Patterns of response and progression to immunotherapy. Am Soc Clin Oncol Educ Book. 2018;38:169–78. https://doi.org/10.1200/edbk_200643.

    Article  PubMed  Google Scholar 

  19. Thomas R, Somarouthu B, Alessandrino F, Kurra V, Shinagare AB. Atypical response patterns in patients treated with nivolumab. AJR Am J Roentgenol. 2019;212:1–5. https://doi.org/10.2214/ajr.18.20938.

    Article  Google Scholar 

  20. Ma Y, Wang Q, Dong Q, Zhan L, Zhang J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019;9(8):1546–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Bai R, Li W, Du N, Cui J. Challenges of evaluating immunotherapy efficacy in solid tumors. Chin J Cancer Res. 2019;31(6):853–61. https://doi.org/10.21147/j.issn.1000-9604.2019.06.02.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20. https://doi.org/10.1158/1078-0432.Ccr-09-1624.

    Article  CAS  PubMed  Google Scholar 

  23. Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388–97. https://doi.org/10.1093/jnci/djq310.

  24. Hamid O, Urba WJ, Yellin M, Nichol GM, Weber J, Hersh EM, et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. J Clin Oncol. 2007;25(18_suppl):8525. https://doi.org/10.1200/jco.2007.25.18_suppl.8525.

    Article  Google Scholar 

  25. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–8. https://doi.org/10.1158/1078-0432.Ccr-16-1741.

  26. Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4(11):1543–52. https://doi.org/10.1001/jamaoncol.2018.3676.

  27. Matos I, Martin-Liberal J, Hierro C, Olza MOD, Viaplana C, Costa M, et al. Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials. J Clin Oncol. 2018;36(15_suppl):3032. https://doi.org/10.1200/JCO.2018.36.15_suppl.3032.

    Article  Google Scholar 

  28. Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci. 2019;116(20):9999–10008. https://doi.org/10.1073/pnas.1822001116.

  29. Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, et al. Genome-wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in cancer patients. Mol Cancer Ther. 2019;18(2):448–58. https://doi.org/10.1158/1535-7163.Mct-18-0535.

  30. Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38–47. https://doi.org/10.1016/j.ejca.2017.10.017.

  31. Vaflard P, Paoletti X, Servois V, Pons-Tostivint E, Sablin MP, Ricci F, et al. Dissociated responses in patients with metastatic solid tumours treated with immunotherapy. Ann Oncol. 2019;30:v521. https://doi.org/10.1093/annonc/mdz253.107.

  32. Tozuka T, Kitazono S, Sakamoto H, Yoshida H, Amino Y, Uematsu S, et al. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. BMC Cancer. 2020;20(1):207. https://doi.org/10.1186/s12885-020-6704-z.

  33. Dong ZY, Zhai HR, Hou QY, Su J, Liu SY, Yan HH, et al. Mixed responses to systemic therapy revealed potential genetic heterogeneity and poor survival in patients with non-small cell lung Cancer. Oncologist. 2017;22(1):61–9. https://doi.org/10.1634/theoncologist.2016-0150.

  34. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627–39. https://doi.org/10.1056/NEJMoa1507643.

  35. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. https://doi.org/10.1056/NEJMoa1613683.

  36. Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67. https://doi.org/10.1016/s0140-6736(18)31999-8.

    Article  CAS  PubMed  Google Scholar 

  37. Mulkey F, By K, Theoret MR, Maher VE, Pazdur R, Sridhara R. Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: a systematic analysis by the United States Food and Drug Administration (FDA). J Clin Oncol. 2019;37(15_suppl):2516. https://doi.org/10.1200/JCO.2019.37.15_suppl.2516.

    Article  Google Scholar 

  38. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.

    Article  CAS  PubMed  Google Scholar 

  39. WHO Handbook. For reporting results of Cancer treatment. Geneva: World Health Organization; 1979.

    Google Scholar 

  40. Thiesse P, Ollivier L, Stefano-Louineau DD, Négrier S, Savary J, Pignard K, et al. Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 1997;15(12):3507–14. https://doi.org/10.1200/jco.1997.15.12.3507.

    Article  CAS  PubMed  Google Scholar 

  41. Baar J, Tannock I. Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials. J Clin Oncol. 1989;7(7):969–78. https://doi.org/10.1200/jco.1989.7.7.969.

    Article  CAS  PubMed  Google Scholar 

  42. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16. https://doi.org/10.1093/jnci/92.3.205.

  43. Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, et al. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer. 2009;45(2):248–60. https://doi.org/10.1016/j.ejca.2008.10.027.

  44. Choi JH, Ahn MJ, Rhim HC, Kim JW, Lee GH, Lee YY, et al. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer Res Treat. 2005;37(5):290–3. https://doi.org/10.4143/crt.2005.37.5.290.

  45. Mazumdar M, Smith A, Schwartz LH. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol. 2004;57(4):358–65. https://doi.org/10.1016/j.jclinepi.2003.07.015.

    Article  PubMed  Google Scholar 

  46. Tuma RS. New response criteria proposed for immunotherapies. J Natl Cancer Inst. 2008;100(18):1280–1. https://doi.org/10.1093/jnci/djn334.

    Article  PubMed  Google Scholar 

  47. Kurra V, Sullivan RJ, Gainor JF, Hodi FS, Gandhi L, Sadow CA, et al. Pseudoprogression in cancer immunotherapy: rates, time course and patient outcomes. J Clin Oncol. 2016;34(15_suppl):6580. https://doi.org/10.1200/JCO.2016.34.15_suppl.6580.

    Article  Google Scholar 

  48. Somarouthu B, Lee SI, Urban T, Sadow CA, Harris GJ, Kambadakone A. Immune-related tumour response assessment criteria: a comprehensive review. Br J Radiol. 2018;91(1084):20170457. https://doi.org/10.1259/bjr.20170457.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Nishino M. Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment. J Immunother Cancer. 2016;4(1):30. https://doi.org/10.1186/s40425-016-0134-0.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510–7. https://doi.org/10.1200/jco.2015.64.0391.

  51. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19(14):3936–43. https://doi.org/10.1158/1078-0432.Ccr-13-0895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Nishino M, Gargano M, Suda M, Ramaiya NH, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014;2:17. https://doi.org/10.1186/2051-1426-2-17.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Bohnsack O, Hoos A, Ludajic K. Adaptation and modification of the immune related response criteria (IRRC): IrRECIST. J Clin Oncol. 2014;32(15_suppl):e22121. https://doi.org/10.1200/jco.2014.32.15_suppl.e22121.

    Article  Google Scholar 

  54. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–52. https://doi.org/10.1016/s1470-2045(18)30351-6.

  55. Trials.gov C. https://clinicaltrials.gov/ct2/show/results/NCT02108652. Accessed March, 2020.

  56. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. https://doi.org/10.1016/s0140-6736(16)00561-4.

  57. Le Lay J, Jarraya H, Lebellec L, Penel N. irRECIST and iRECIST: the devil is in the details. Ann Oncol. 2017;28(7):1676–8. https://doi.org/10.1093/annonc/mdx168.

    Article  PubMed  Google Scholar 

  58. Ferte C, Marabelle A. iRECIST: a clarification of tumour response assessment in the immunotherapy era. Eur J Cancer. 2017;77:165–7. https://doi.org/10.1016/j.ejca.2017.02.015.

    Article  PubMed  Google Scholar 

  59. • Mulkey F, Theoret MR, Keegan P, Pazdur R, Sridhara R. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. J Immunother Cancer. 2020;8(1). https://doi.org/10.1136/jitc-2019-000146. Pooled analysis based on largest database of RCTs of immunotherapy trials submitted for FDA approval. This article reports the response rates based on iRECIST and RECIST 1.1 criteria based on raw tumor measurements.

  60. Beer L, Hochmair M, Haug AR, Schwabel B, Kifjak D, Wadsak W, et al. Comparison of RECIST, iRECIST, and PERCIST for the evaluation of response to PD-1/PD-L1 blockade therapy in patients with non–small cell lung Cancer. Clin Nucl Med. 2019;44(7):535–43. https://doi.org/10.1097/rlu.0000000000002603.

  61. Mazieres J, Fehrenbacher L, Rittmeyer A, Spira AI, Park K, Smith DA, et al. Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: results from the randomized phase II study POPLAR. J Clin Oncol. 2016;34(15_suppl):9032. https://doi.org/10.1200/JCO.2016.34.15_suppl.9032.

    Article  Google Scholar 

  62. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. https://doi.org/10.1016/s0140-6736(16)32517-x.

  63. Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018;36(9):850–8. https://doi.org/10.1200/jco.2017.75.1644.

  64. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373(2):123–35. https://doi.org/10.1056/NEJMoa1504627.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Kazandjian D, Keegan P, Suzman DL, Pazdur R, Blumenthal GM. Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1–defined disease progression in clinical trials. Semin Oncol. 2017;44(1):3–7. https://doi.org/10.1053/j.seminoncol.2017.01.001.

    Article  CAS  PubMed  Google Scholar 

  66. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland A, Han JY, et al. Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study. J Thorac Oncol. 2018;13(12):1906–18. https://doi.org/10.1016/j.jtho.2018.08.2027.

  67. Artal-Cortes A, Mazieres J, Fehrenbacher L, Rittmeyer A, Spira AI, Park K, et al. 96PD_PR - Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: results from the randomized phase II study POPLAR. Ann Oncol. 2017;28:ii35. https://doi.org/10.1093/annonc/mdx091.016.

    Article  Google Scholar 

  68. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46. https://doi.org/10.1016/s0140-6736(16)00587-0.

  69. Cappuzzo F, Delmonte A, Capici S, Crinò L, Logroscino AF, Sandri P, et al. P1.06-006 treatment beyond progression in patients with advanced squamous NSCLC participating in the expanded access programme (EAP): topic: advanced general. J Thorac Oncol. 2017;12(1):S667–S8. https://doi.org/10.1016/j.jtho.2016.11.870.

  70. Genova C, Rijavec E, Rossi G, Biello F, Barletta G, Tagliamento M, et al. Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression. Ann Oncol. 2017;28:vi61. https://doi.org/10.1093/annonc/mdx426.023.

    Article  Google Scholar 

  71. • Reinhorn D, Jacobi O, Icht O, Dudnik E, Rotem O, Zer A, et al. Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer. Immunotherapy. 2020;12(4):235–43. A retrospective study in advanced NSCLC patients evaluating TBP benefit when treated with ICI in addition to the use of radiotherapy or surgery as a second modality.

  72. • Beaver JA, Hazarika M, Mulkey F, Mushti S, Chen H, He K, et al. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2018;19(2):229–39. One of the largest pooled analysis evaluating benefit of TBP in melanoma patients, highlighting the variations in assessing TBP benefit.

  73. George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol. 2016;2(9):1179–86. https://doi.org/10.1001/jamaoncol.2016.0775.

  74. Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol. 2017;72(3):368–76. https://doi.org/10.1016/j.eururo.2017.03.037.

  75. Cortesi E, Cappuzzo F, Galli L, Bearz A, Pignata S, Berruti A, et al. 892PTreatment beyond progression in patients with advanced RCC participating in the expanded access programme (EAP). Ann Oncol. 2017;28:v316. https://doi.org/10.1093/annonc/mdx371.046.

  76. Necchi A, Joseph RW, Loriot Y, Hoffman-Censits J, Perez-Gracia JL, Petrylak DP, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044–50. https://doi.org/10.1093/annonc/mdx518.

  77. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22. https://doi.org/10.1016/S1470-2045(17)30065-7.

  78. Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, et al. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: a subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019;125(18):3208–18. https://doi.org/10.1002/cncr.32190.

    Article  CAS  PubMed  Google Scholar 

  79. Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies. JAMA Oncol. 2018;4(5):717–21. https://doi.org/10.1001/jamaoncol.2017.5332.

  80. Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, et al. Immuno-oncology trial endpoints: capturing clinically meaningful activity. Clin Cancer Res. 2017;23(17):4959–69. https://doi.org/10.1158/1078-0432.Ccr-16-3065.

  81. Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. 2020;8(1):e000398. https://doi.org/10.1136/jitc-2019-000398.

  82. Blumenthal GM, Theoret MR, Pazdur R. Treatment beyond progression with immune checkpoint inhibitors-known unknowns. JAMA Oncol. 2017;3(11):1473–4. https://doi.org/10.1001/jamaoncol.2017.1819.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Sirisha L. Mushti and Flora Mulkey contributed equally to this work.

Authors and Affiliations

  1. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA

    Sirisha L. Mushti, Flora Mulkey, Shenghui Tang, Harpreet Singh, Steven J. Lemery, Paul G. Kluetz, Richard Pazdur, Marc R. Theoret & Julia A. Beaver

  2. Oncology Center of Excellence, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA

    Kirsten B. Goldberg, Patricia Keegan, Paul G. Kluetz, Richard Pazdur, Marc R. Theoret & Julia A. Beaver

  3. Oncology Center of Excellence (Contractor), Brillient Corporation, Reston, USA

    Rajeshwari Sridhara

Authors
  1. Sirisha L. Mushti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Flora Mulkey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shenghui Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harpreet Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Steven J. Lemery
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kirsten B. Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rajeshwari Sridhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Patricia Keegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paul G. Kluetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Richard Pazdur
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Marc R. Theoret
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Julia A. Beaver
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sirisha L. Mushti.

Ethics declarations

Conflict of Interest

None of the authors has any potential conflicts of interest to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Immuno-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mushti, S.L., Mulkey, F., Tang, S. et al. Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Curr Oncol Rep 22, 116 (2020). https://doi.org/10.1007/s11912-020-00974-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-020-00974-z

Keywords

Search

Navigation